Aztiq, an Iceland-based healthcare investor headed by Alvogen founder and chairman Róbert Wessman, and Innobic (Asia) Company Limited, a life sciences subsidiary of Thailand industrial group PTT, announced on Friday that they have signed a definitive agreement to acquire a 100% share in in Alvogen Emerging Market Holdings Limited (AEMH) from its present shareholders.
The deal is valued at USD475m.
According to the partners, the deal is intended to create a powerful pharmaceuticals enterprise with global resources, networks and reach. Through the transaction, the consortium becomes the leading shareholder in the global oncology pharmaceutical company Lotus Pharmaceutical (Lotus, TWSE ticker: 1795), and the sole shareholder in Alvogen Malta Holding Ltd., the owner of the fast-growing global business to business (B2B) pharmaceutical company Adalvo.
Robert Wessman, Aztiq's founder and chairman, is to continue serving as chairman of the board of Lotus and Adalvo.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories